Published • loading... • Updated
SELUTION SLR DEB Wins US FDA Approval for In-Stent Restenosis - Cofounder Amit Bohora Calls It
Summary
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
bhaskarlive.inReposted by 
up18news.com
up18news.comSELUTION SLR™ DEB Wins US FDA Approval for In-Stent Restenosis – Cofounder Amit Bohora Calls It “A Defining Milestone for Stentless Cardiac Care”
<p>The technology Amit Bohora co-founded at MedAlliance, and later sold to Cordis in a landmark USD 1.135 Billion deal, has just become the first and only sirolimus drug-eluting balloon approved</p>
brazilsun.comReposted by 
southamericanews.net
southamericanews.netSELUTION SLR DEB Wins US FDA Approval for In-Stent Restenosis - Cofounder Amit Bohora Calls It
The U.S. Food and Drug Administration has approved the SELUTION SLR (Sustained Limus Release) Drug-Eluting Balloon for coronary in-stent restenosis (ISR), Cordis announced this month - making it the first and only sirolimus drug-eluting balloon approved for use anywhere in the United States. For Amit Bohora, who co-founded MedAlliance and helped take SELUTION SLR from an early research concept to a globally commercialized therapy before the comp…
Coverage Details
Total News Sources4
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
